PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2143375
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2143375
Histidine Tag (His-Tag) Antibody market size was valued at US$ 1,405.9 Million in 2025, expanding at a CAGR of 10.9% from 2026 to 2033.
The His-tag antibody is a unique antibody that recognizes the hexahistidine sequence tag that has been genetically incorporated into the protein of interest. This antibody serves as a generic probe in any experiments that involve the manipulation of recombinant proteins. The construction of a typical His-tag antibody consists of the general Y-shaped structure of the IgG and a Fab portion that specifically binds to the oligohistidine sequence in the target protein. On the other hand, the Fc region of the His-tag antibody is conserved and common, and therefore it can be labeled with an enzyme for detection or conjugated with an affinity matrix. Thus, His-tag antibodies enable reliable detection, purification, and analysis of recombinant proteins across diverse applications.
Histidine Tag (His-Tag) Antibody Market- Market Dynamics
Growing Demand For Biopharmaceuticals To Propel Market Demand
The growing demand for biopharmaceuticals is fueling the Histidine Tag (His-Tag) Antibody market due to the rise in the production of recombinant proteins, increase in the usage of affinity purification processes, and need for effective isolation of proteins for biopharmaceutical research and manufacturing. In October 2025, according to the Office for Life Sciences, UK Government, the UK life sciences industry consists of 6,170 companies in 7,320 businesses, employing 359,600 people with turnover ($199,607.1 million). The biopharmaceutical industry accounts for 2,960 companies, accounting for 40% of total companies in the UK life sciences industry. These companies have 163,600 employees, accounting for 45% of total employment in life sciences in the UK. Among all companies in the UK life sciences industry, of turnover ($134,405.1 million) accounts for 67% of the total turnover of the UK life sciences industry. The rising demand for biopharmaceuticals is fast driving the histidine tag antibody market.
The Global Histidine Tag (His-Tag) Antibody market is segmented on the basis of Product Type, Application, End User, and Region.
Under Product Type, monoclonal antibodies play a key role because the monoclonal antibodies will be used to offer high specificity to detect the protein and reproducible and reliable purification and analysis for His-tagged recombinant proteins. In April 2025, Bio-Techne came up with His Tag Antibody (RM146), and it is used for the recognition of recombinant proteins that are tagged with a 6XHis or 10XHis tag, and it can be used in Western blotting, flow cytometry, immunoprecipitation, etc. This advancement strengthens antibody performance, supporting precise detection and analysis of His-tagged recombinant proteins.
Histidine Tag (His-Tag) Antibody Market- Geographical Insights
North American academic organizations and biotechnology organizations are highly affected by the use of specific imported reagents, causing possible challenges in the supply chain and procurement. For instance, in October 2025, according to the DCAT Value Chain Insights report (Org.), venture capital investment in biotechnology in the U.S. and Europe was seen to be moving toward "higher" numbers, with $15,500 million raised for early-stage ventures and $7,600 million for late-stage ventures year-to-date, significantly more than before the pandemic. Furthermore, according to the report, 30 biotech companies had raised $4,000 million via IPOs with 18 that raised $2,900 million. Although there was an improvement, IPO activity still lagged behind the average of 54 per year. Moreover, biotech alliances also became one of the growth tools, with pharmaceutical companies signing 220 alliances, showing potential deal value of $144,000 million in biobucks. This funding momentum is expected to strengthen biotechnology innovation and demand for specialized reagents.
The Asian Pacific also faces costs associated with exporting focused on the manufacture of antibody production tariffs will cause the cost of research and manufacturing to be expensive and order time to be extended. For instance, in November 2025, according to the U.S. International Trade Administration, it was estimated that the Japanese market for pharmaceuticals would have been worth ($87,373 million), with total pharmaceutical exports worth ($8,981 million) and total imports worth ($33,187 million). The report indicates a strong opportunity for exporting through the development of antibodies, where 90% of the marketed antibodies in Japan are manufactured overseas, indicating dependence on the manufacture of foreign sources. The market of biopharmaceuticals and regenerative medicine in Japan was estimated to be 1.5 trillion yen, and by 2030, the prediction of the market is expected to exceed 3.3 trillion yen, indicating an expectation of a high growth rate of the biopharmaceutical manufacturing industry towards antibody production. These factors are expected to strengthen Japan's antibody manufacturing and biopharmaceutical production capabilities.
Major companies operating in the Histidine Tag (His-Tag) Antibody market include Thermo Fisher Scientific Inc., Danaher Corporation, Merck KGaA, Bio-Rad Laboratories Inc., and GeneTex Inc. The above companies produce His-tag antibodies, which can be used in the processes of detection, purification, and further analysis of His-tagged recombinant proteins and other experiments. In April 2026, Thermo Fisher Scientific Inc. introduced his-tag antibody, 6x-His Tag Monoclonal Antibody (HIS.H8), DyLight 680 conjugate, which can be used in detecting His-tagged recombinant proteins by methods such as Western Blotting and Immunohistofluorescence (IHF). These innovations indicate increased innovation in the use of His-tag antibodies in current scientific research.
In September 2025, Proteintech introduced Able AI, an artificial intelligence research tool, which provides customized recommendations of products as well as suggestions regarding experimental designs by virtue of validating antibodies and selecting products for them.
In March 2025, Cell Signaling Technology started working in collaboration with Leveragen Inc. in order to develop new technologies related to the development of reagents-antibodies-through Leveragen's Singularity Musculus nanobody technology.